FDA expands accelerated approval of Hyrnuo for untreated HER2-mutant advanced NSCLC

The FDA has expanded accelerated approval of Bayer's Hyrnuo to previously untreated adults with a specific HER2-mutant form of advanced non-small cell lung cancer.

More News